Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130950 | 0.82 | SRC (0.41) | SRCALDH1A1CYP2C19CYP2D6DPP4 | |
| SCHEMBL5555050 | 0.78 | SRC (0.39) | SRCALDH1A1CYP2C19CYP2D6DPP4 | |
| SCHEMBL3633092 | 0.78 | ALDH1A1 (0.42) | SRCALDH1A1CYP2C19CYP2D6DPP4 | |
| SCHEMBL5555043 | 0.78 | SRC (0.39) | SRCALDH1A1CYP2C19CYP2D6DPP4 | |
| SCHEMBL9006009 | 0.78 | CA1 (0.42) | SRCALDH1A1DPP4F2 | |
| SCHEMBL669211 | 0.78 | SRC (0.54) | SRCALDH1A1CYP2C19CYP2D6TSHR | |
| SCHEMBL1858357 | 0.77 | SRC (0.41) | SRCFAAHPRSS1PRSS2ELANE | |
| SCHEMBL8520306 | 0.77 | CYP2C19 (0.48) | SRCFAAHPRSS1PRSS2ELANE | |
| SCHEMBL16058363 | 0.75 | APOBEC3G (0.40) | SRCALDH1A1CYP2C19CYP2D6LMNA | |
| SCHEMBL3083627 | 0.73 | ALDH1A1 (0.41) | SRCFAAHPRSS1PRSS2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9684001-B2 | Biomarkers for head-and-neck cancers and precancers | RALHAN RANJU (CA) | 2017-06-20 | — | — | US | disclosed |
| EP-2949790-A1 | BIOMARKERS FOR HEAD-AND-NECK CANCERS AND PRECANCERS | Ralhan, Ranju (CA) | 2015-12-02 | — | — | EP | disclosed |
| EP-2252729-B1 | BIOMARKERS FOR HEAD-AND-NECK CANCERS AND PRECANCERS | RALHAN RANJU (CA) | 2015-05-27 | — | — | EP | disclosed |
| US-20150057169-A1 | Biomarkers for Head-and-Neck Cancers and Precancers | SIU, K.W. MICHAEL (CA) | 2015-02-26 | — | — | US | disclosed |
| US-8921053-B2 | Biomarkers for head-and-neck cancers and precancers | WALFISH, PAUL (CA) | 2014-12-30 | — | — | US | disclosed |
| US-20140080138-A1 | Biomarkers for Head-and-Neck Cancers and Precancers | RALHAN RANJU (CA) | 2014-03-20 | — | — | US | disclosed |
| US-8420794-B2 | Anti-influenza M2e antibody | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120064085-A1 | ANTI-INFLUENZA M2e ANTIBODY | LOS ALAMOS NATIONAL SECURITY, LLC | 2012-03-15 | — | — | US | disclosed |
| US-20110104062-A1 | Biomarkers for Head-And-Neck Cancers and Precancers | Siu, K. W. Michael (CA) | 2011-05-05 | — | — | US | disclosed |
| EP-2252729-A1 | BIOMARKERS FOR HEAD-AND-NECK CANCERS AND PRECANCERS | Siu, Michael K. W. (CA) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009097692-A1 | BIOMARKERS FOR HEAD-AND-NECK CANCERS AND PRECANCERS | SIU K W MICHAEL (CA) | 2009-08-13 | — | — | WO | disclosed |
| EP-0116472-B1 | ANTIGENIC MATERIALS | COUNCIL OF GOVERNORS OF THE UNITED MEDICAL AND DENTAL SCHOOLS OF GUY'S AND ST. THOMAS'S HOSPITALS (GB) | 1989-04-26 | — | — | EP | disclosed |
| US-4594244-A | Antigenic materials | COUNCIL OF GOVERNORS OF THE UNITED MEDICAL AND DENTAL SCHOOLS OF GUY'S AND ST. THOMAS'S HOSPITALS (GB) | 1986-06-10 | — | — | US | disclosed |
| EP-0116472-A2 | Antigenic materials | COUNCIL OF GOVERNORS OF THE UNITED MEDICAL AND DENTAL SCHOOLS OF GUY'S AND ST. THOMAS'S HOSPITALS (GB) | 1984-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104062-A1 | Biomarkers for Head-And-Neck Cancers and Precancers | CHI3L1, CCL2, LGALS3 | SRC 3851/4885FAAH 4186/4885PRSS1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.